Hcw biologics announces 1-for-40 reverse stock split

Miramar, fla., april 01, 2025 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that its board of directors has approved a 1-for-40 reverse stock split of the company's common stock, par value $0.0001 (“common stock”), which will be effective at 12:01 a.m. eastern time on april 11, 2025. the company's common stock will be traded on the nasdaq capital market on a reverse split-adjusted basis beginning on april 11, 2025, under the company's existing trading symbol “hcwb.”
HCWB Ratings Summary
HCWB Quant Ranking